Johnson & Johnson (JNJ)
| Previous close | 146.82 |
| Open | 146.88 |
| Bid | 145.24 x 800 |
| Ask | 145.25 x 900 |
| Day's range | 144.85 - 146.88 |
| 52-week range | 143.13 - 175.97 |
| Volume | |
| Avg. volume | 7,641,806 |
| Market cap | 349.418B |
| Beta (5Y monthly) | 0.53 |
| PE ratio (TTM) | 19.52 |
| EPS (TTM) | 7.43 |
| Earnings date | 17 Jul 2024 |
| Forward dividend & yield | 4.96 (3.38%) |
| Ex-dividend date | 20 May 2024 |
| 1y target est | 162.28 |
- Reuters
J&J, Bristol Myers lose challenges to US drug price negotiation program
A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties. U.S. District Judge Zahid Quraishi in Trenton, New Jersey, became the fourth federal judge to uphold the program, one of Democratic President Joe Biden's signature initiatives, against drug industry challenges, rejecting their argument that it was an illegal taking of their property. "In short, defendants are not taking drugs from plaintiffs," Quraishi wrote, adding that they were free to stop participating in Medicare if they did not want to negotiate.
Simply Wall St.Johnson & Johnson's (NYSE:JNJ) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
It is hard to get excited after looking at Johnson & Johnson's (NYSE:JNJ) recent performance, when its stock has...
Insider MonkeyDividend Stock Portfolio For Income: Top 15 Stocks
In this article, we will discuss dividend stocks for regular income. You can skip our detailed analysis of dividend stocks and their historical performance, and go directly to read Dividend Stock Portfolio For Income: Top 5 Stocks. It is generally believed that dividend stocks are primarily suitable for people approaching retirement. However, this is far from […]
